NEW YORK, April 19 (Reuters) - As Valeant Pharmaceuticals
considers a multibillion-dollar auction to pare down $30 billion
in debt, its challenge will be choosing which assets to sell
without compromising any of its key businesses, analysts and
investment bankers said.
Read more
No comments:
Post a Comment